The Effect of Antigen Dose and Antigen Presenting Process on T Cell Stimulation: A Method for Enrichment of TB10.4 Antigen-specific T-cell Clones
T-lymphocytes have critical functions in the immune responses against viral and intracellular bacterial infections as well as cancers. Antigen (Ag)-specific T-lymphocyte clones enriched and expanded in vitro are valuable tools in the study of immune responses in animal models and adoptive T-cell therapy of patients with cancer or infection.
We described a method for inducing, enriching, and replicating Ag-specific poly-clonal T-cells from BALB/c mice infected with live Bacillus Calmette Guérin (BCG) bacterium. During a 7-8 days procedure, T-lymphocytes were purified from immune cells of lymph nodes stimulated with immunodominant Ag of BCG, TB10.4, and expanded by interleukin -2 cytokine. We evaluated the effect of Ag doses (1, 10, and 100 μg/mL) and exposure method of Ag presenting cells (APCs) to T-cells, on T-cells’ proliferation, viability, and Interferon-gamma (IFN-γ) secretion at 2, 5, and 7 days after Ag stimulation.
Increasing Ag concentration increased the average cell division, but at the highest dose of Ag (100 μg/mL), T-cell viability is decreased. Only clones induced by 10 μg/mL Ag produced a desirable amount of IFN-γ. Incubation of Ag and APCs, 24 h before T-lymphocytes addition, increased the proliferation and viability of cells. T cells are in a more favorable condition around day 5 of Ag stimulation in terms of proliferation and survival, and it is the desired time for T cell restimulation.
For optimal preparation of specific T-cells for adoptive cell transfer, optimization of Ag dose, the order of APCs and T-cells exposure with Ag, and the duration of initial Ag stimulation, as well as the time for restimulation, is essential.
2. Messaoudi I, Patino JAG, Dyall R, LeMaoult J, Nikolich-Žugich J. Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science. 2002;298(5599):1797-800.
3. Speiser DE, Liénard D, Pittet MJ, Batard P, Rimoldi D, Guillaume P, et al. In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol. 2002;32(3):731-41.
4. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020:1-18.
5. Yee C. Adoptive Therapy Using Antigen-Specific T-Cell Clones. Cancer J. 2010;16(4):367-73.
6. Wei J, Han X, Bo J, Han W. Target selection for CAR-T therapy. J Hematol Oncol. 2019;12(1):1-9.
7. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-7.
8. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-35.
9. Rothoeft T, Gonschorek A, Bartz H, Anhenn O, Schauer U. Antigen dose, type of antigen-presenting cell and time of differentiation contribute to the T helper 1/T helper 2 polarization of naive T cells. Immunology. 2003;110(4):430-9.
10. Nikolich-Žugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol. 2004;4(2):123-32.
11. Labarrière N, Fortun A, Bellec A, Khammari A, Dreno B, Saiagh S, et al. A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma. Clin Dev Immunol. 2013;2013.
12. Lim JF, Berger H, Su IH. Isolation and Activation of Murine Lymphocytes. J Vis Exp. 2016(116):54596.
13. Hensel JA, Khattar V, Ashton R, Ponnazhagan S. Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations. Lab Invest. 2019;99(1):93-106.
14. Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas M-J, Nouzé C, et al. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun. 2006;74(6):3396-407.
15. Skjøt RLV, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as Immunodominant T-cell antigens. Infect Immun. 2000;68(1):214-20.
16. Skjøt RLV, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff TH, et al. Epitope mapping of the immunodominant antigen TB10. 4 and the two homologous proteins TB10. 3 and TB12. 9, which constitute a subfamily of the esat-6 gene family. Infect Immun. 2002;70(10):5446-53.
17. Gholoobi A, Sankian M, Zarif R, Farshadzadeh Z, Youssefi F, Sadeghian A, et al. Molecular cloning, expression and purification of protein TB10. 4 secreted by mycobacterium tuberculosis. Ira J Med Sciences. 2010;13(4):189-93.
18. Hathcock KS. T cell enrichment by nonadherence to nylon. Curr Protoc Immunol. 1999;30(1):3.2. 1-3.2. 4.
19. Zanganeh E, Soudi S, Zavaran Hosseini A, Khosrojerdi A. Repeated intravenous injection of adipose tissue derived mesenchymal stem cells enhances Th1 immune responses in Leishmania major-infected BALB/c mice. Immunol Lett. 2019;216:97-105.
20. Neller MA, Lai MH-L, Lanagan CM, Linda E, Pritchard AL, Martinez NR, et al. High efficiency ex vivo cloning of antigen-specific human effector T cells. PloS one. 2014;9(11):e110741.
21. Van Heijst JWJ, Gerlach C, Swart E, Sie D, Nunes-Alves C, Kerkhoven RM, et al. Recruitment of Antigen-Specific CD8+ T Cells in Response to Infection Is Markedly Efficient. Science. 2009;325(5945):1265-9.
22. Kim M, Moon H-B, Kim K, Lee K-Y. Antigen dose governs the shaping of CTL repertoires in vitro and in vivo. Int Immunol. 2006;18(3):435-44.
23. Henrickson SE, Mempel TR, Mazo IB, Liu B, Artyomov MN, Zheng H, et al. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol. 2008;9(3):282-91.
24. Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545-58.
25. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med. 1995;182(5):1579-84.
26. Critchfield J, Racke M, Zuniga-Pflucker J, Cannella B, Raine C, Goverman J, et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 1994;263(5150):1139-43.
27. Iezzi G, Karjalainen K, Lanzavecchia A. The Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells. Immunity. 1998;8(1):89-95.
28. Meier S, Stark R, Frentsch M, Thiel A. The influence of different stimulation conditions on the assessment of antigen-induced CD154 expression on CD4+ T cells. Cytometry A. 2008;73A(11):1035-42.
29. Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wieczorek G, et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol. 2009;39(4):1088-97.
|Issue||Vol 20 No 3 (2021)|
|Antigens Antigen-presenting cells Cell- and tissue-based therapy Clone cells Immunotherapy T-lymphocytes|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|